Njomatchoua Audrey Carine, Tankeu Aurel Tiakouang, Sobngwi Eugene, Mbanya Jean-Claude
Cameroon National Obesity Center, Yaoundé Central Hospital, Yaoundé, Cameroon.
Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
BMC Res Notes. 2017 Aug 24;10(1):423. doi: 10.1186/s13104-017-2744-0.
We aimed to quantify the glycemic effects of quinine in healthy individuals.
We evaluated the glycemic profile in response to 4 h infusion of 500 ml of 0.9% saline versus 5% glucose solution with and without quinine at therapeutic dose (500 mg) in ten healthy volunteers (8 men) aged 28 ± 9 years. The order of the fourth explorations was randomly assigned. During these explorations, we measured blood glucose every 15 min for 4 h and compared the mean and glycemic fluctuations for each test. A resting ECG was performed before and after quinine infusion in each participant.
The mean glycemic level during the 4-h infusion was 83 ± 5 mg/dl without quinine versus 74 ± 5 mg/dl with quinine (p < 0.001) using saline solute versus 92 ± 7 mg/dl without quinine versus 82 ± 5 mg/dl with quinine (p < 0.001) when associated with the glucose solute. In isotonic dirty solute, quinine induces a cumulative glycemic decrease of 17.5% (p = 0.01) characterized by a nadir estimated at -26.5% at the 60th minute (65 ± 23 mg/dl), p <0.001 followed by a gradual increase until the 4th hour. There were no signs of hypoglycemia or significant prolongation of the QT interval at the ECG. Overall, quinine did not induce a significant change in blood glucose with glucose compared to saline.
The intravenous infusion of quinine at a therapeutic dose induces a light drop in blood glucose with a significant nadir at the 60th minute in the healthy subject without hypoglycemia. This suggests the need for close monitoring in patients at risk of hypoglycemia such as those with severe malaria especially during the first hour of quinine infusion.
我们旨在量化奎宁对健康个体的血糖影响。
我们评估了10名年龄为28±9岁的健康志愿者(8名男性)在输注500毫升0.9%生理盐水与5%葡萄糖溶液4小时时的血糖情况,其中葡萄糖溶液添加或不添加治疗剂量(500毫克)的奎宁。第四次试验的顺序是随机分配的。在这些试验期间,我们在4小时内每隔15分钟测量一次血糖,并比较每次试验的平均值和血糖波动情况。在每位参与者输注奎宁前后进行静息心电图检查。
使用生理盐水溶质时,4小时输注期间无奎宁时的平均血糖水平为83±5毫克/分升,有奎宁时为74±5毫克/分升(p<0.001);与葡萄糖溶质联合使用时,无奎宁时为92±7毫克/分升,有奎宁时为82±5毫克/分升(p<0.001)。在等渗生理盐水溶质中,奎宁导致血糖累计下降17.5%(p=0.01),其最低点估计在第60分钟时为-26.5%(65±23毫克/分升),p<0.001,随后逐渐上升直至第4小时。心电图检查未发现低血糖迹象或QT间期显著延长。总体而言,与生理盐水相比,奎宁与葡萄糖联合使用时未引起血糖的显著变化。
在健康受试者中,以治疗剂量静脉输注奎宁会导致血糖轻度下降,在第60分钟时出现显著最低点,且无低血糖情况。这表明对于有低血糖风险的患者,如重症疟疾患者,尤其是在奎宁输注的第一小时期间,需要密切监测。